Biologically Active Adrenomedullin (bio-ADM) is of potential value in identifying congestion and selecting patients for neurohormonal blockade in acute dyspnea

Dyspnea accounts for 5% of total emergency department visits, two-thirds of which require hospitalisation1. The in-hospital mortality rate of dyspneic patients remains relatively high and reaches 5-6%1,2. Moreover, a half of acute dyspnea patients are readmitted within 6 months, and readmission is closely related to a dramatically increased risk of death, irrespective of the initial cause of dyspnea3. Conventional signs and symptoms accompanying dyspnea are of limited value in differential diagnostics and risk stratification4.

Source: The American Journal of Medicine - March 1, 2022 Category: General Medicine Authors: Justas Simonavi čius, Aurimas Mikalauskas, Kamilė Čerlinskaitė, Etienne Gayat, Vytautas Juknevičius, Eglė Palevičiūtė, Irina Alitoit-Marrote, Denis Kablučko, Loreta Bagdonaitė, Mindaugas Balčiūnas, Dovilė Vaičiulienė, Ieva Jonauskienė, Ju Tags: Clinical Research Study Source Type: research